Adenovector Selectivity: Selective Transduction VLI has developed technology to modify the adenovector outer coat proteins for the selective transduction of immune and tumor cells for increased efficacy and safety. This type of molecular targeting is achieved through adding ligands to the vector that recognize tissue- or disease-specific receptors selectively expressed on the target cells. The effective transduction of immune cells increases vaccine immunogenicity with a corresponding increase in protection against the specific diseases. Such molecular targeting strategies could be used for the treatment of disseminated diseases such as cancer metastasis. VLI is developing products that specifically target dendritic cells for effective cancer vaccine therapeutics. Modified Adenovectors